Stock Data
$0.43 (2.69%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
MEDICAL DEVICES
NovoCure Ltd specializes in innovative cancer treatment technologies, focusing on its unique Tumor Treating Fields (TTFields) devices. These devices, including Optune Gio and Optune Lua, are designed to combat solid tumor cancers across various parts of the world. Beyond manufacturing, NovoCure is deeply involved in clinical trials to expand the use of TTFields in treating multiple cancer types, demonstrating its commitment to advancing cancer care. Founded in 2000, the company is based in Saint Helier, Jersey, marking its global footprint in the fight against cancer.
NovoCure crushed expectations with active patients surging 18% to 5,128 and swinging to positive Adjusted EBITDA, sending the cancer therapy company to a $0.13 loss per share that beat estimates by 61%. The company lifted full-year revenue guidance to $710 million to $725 million on the strength of Optune Lua and Optune Pax, which together pulled in $7 million this quarter.
14 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
